Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:09 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formula Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Influenza Vaccination on IVF Outcomes - IVF

NCT02947217
View directory record Official record
Conditions
Infertility
Interventions
Influenza Vaccine, Sterile Saline
Biological · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 38 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 3, 2026, 10:09 AM EST
Withdrawn Phase 1 Interventional

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

NCT04055389
View directory record Official record
Conditions
Portal Vein Thrombosis, Cirrhosis, Liver
Interventions
Antithrombin III, Placebo
Drug · Other
Lead sponsor
Jonathan Stine
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Using the Electronic Health Record to Guide Management of Newborn Weight Loss

NCT03655314
View directory record Official record
Conditions
Breastfeeding, Breastfeeding, Exclusive, Morbidity;Perinatal, Feeding, Bottle
Interventions
NEWT, Usual care
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Hours to 96 Hours
Enrollment
2,682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Nov 3, 2026, 10:09 AM EST
Not listed Phase 2Phase 3 Interventional

The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee

NCT02333084
View directory record Official record
Conditions
Osteoarthritis
Interventions
PRN Joint Health Formula, placebo, PRN Flex Omega Benefits® combination
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Nov 3, 2026, 10:09 AM EST
Terminated Phase 1 Interventional

Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

NCT01300793
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, B-cell Lymphoma
Interventions
Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Nov 3, 2026, 10:09 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of HIIT vs. TRE on Type 2 Diabetes Risk

NCT07215533
View directory record Official record
Conditions
Obesity and Type 2 Diabetes, Metabolic Diseases, High-intensity Interval Training, Time-restricted Eating
Interventions
High-intensity interval training, Time-restricted eating
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
14 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional

Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula

NCT02450643
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
Test extensively hydrolyzed formula, Control extensively hydrolyzed formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
2 Months to 4 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Little Rock, Arkansas • Mission Viejo, California • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 3, 2026, 10:09 AM EST
Completed No phase listed Observational Accepts healthy volunteers

GI Tract Biomarkers in Infants With Different Diets

NCT03751137
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Weeks to 3 Months
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Nov 3, 2026, 10:09 AM EST
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional Results available

A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

NCT03897751
View directory record Official record
Conditions
Contact Lens Wear
Interventions
ABT12 Multi-Purpose Solution, COMPLETE Multi-Purpose Solution, Sensitive Eyes® Rewetting Drops
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Nov 3, 2026, 10:09 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional

Ketogenic Diet for Refractory Status Epilepticus

NCT01796574
View directory record Official record
Conditions
Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Nov 3, 2026, 10:09 AM EST
Recruiting Not applicable Interventional

Impact of Early Fortini Initiation on Growth and Interstage Outcomes in Infants With Single Ventricle Physiology

NCT07087782
View directory record Official record
Conditions
Single-ventricle
Interventions
Fortini formula, Standard Nutritional Care
Other
Lead sponsor
Driscoll Children's Hospital
Other
Eligibility
0 Months to 6 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 3, 2026, 10:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010; paliperidone palmitate, INVEGA SUSTENNA
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Nov 3, 2026, 10:09 AM EST
Terminated Phase 2 Interventional Results available

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390
View directory record Official record
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Postpartum Smoking Relapse Prevention by Breastfeeding Promotion

NCT04670822
View directory record Official record
Conditions
Smoking, Cigarette, Breastfeeding
Interventions
Breastfeeding promotion, Attention placebo control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional

Soy Formula Feedings in Healthy, Term Infants

NCT02456831
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3, Active Comparator: Control Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
2 Weeks to 9 Weeks
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
7
States / cities
Little Rock, Arkansas • Aurora, Illinois • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Nov 3, 2026, 10:09 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas

NCT04059666
View directory record Official record
Conditions
Gastrointestinal Microbiome
Interventions
Investigational, Control
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
7 Days to 18 Days
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Altamonte Springs, Florida • Owensboro, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Nov 3, 2026, 10:09 AM EST
Withdrawn Phase 2 Interventional

IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD

NCT01438372
View directory record Official record
Conditions
Iron Deficiency Anemia, Inflammatory Bowel Disease
Interventions
Intravenous iron sucrose, Oral ferrous sulfate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Nov 3, 2026, 10:09 AM EST
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 3, 2026, 10:09 AM EST
Not listed Not applicable Interventional

Micronutrients as Adjunctive Treatment for Bipolar Disorder

NCT03541031
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Micronutrient & Fish oil, Olive oil & Safflower oil
Dietary Supplement
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 3, 2026, 10:09 AM EST
Completed Phase 2 Interventional

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

NCT00244075
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplement, recombinant human growth hormone (rcGH), exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Nov 3, 2026, 10:09 AM EST
Completed Not applicable Interventional Results available

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

NCT02750501
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
Device · Other
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 3, 2026, 10:09 AM EST
Terminated Phase 1 Interventional Results available

Oral Rehydration Therapy in Burn Patients

NCT02124265
View directory record Official record
Conditions
Burn Any Degree Involving 20-29 Percent of Body Surface, Burn Any Degree Involving 30-39 Percent of Body Surface, Burn Any Degree Involving 40-49 Percent of Body Surface, Burn Any Degree Involving 50-59 Percent of Body Surface, Burn Any Degree Involving 60-65 Percent of Body Surface, Fluid Resuscitation
Interventions
CeraLyte 90
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Nov 3, 2026, 10:09 AM EST